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Background
The iatrogenic risk of HIV vertical transmission, calcu-
lated in initial epidemiologic studies of this infection
seemed to contra-indicate the performance of invasive
prenatal diagnosis (PND) techniques. The implementa-
tion of highly active antiretroviral therapy (HAART)
represented a turning point in PND management, owing
to a rapid and effective reduction of the maternal viral
load.
Purpose of the study
To evaluate the risk of vertical transmission in pregnant
women infected with HIV, submitted to amniocentesis
during the second trimester of pregnancy.
Methods
Analysis of the amniocentesis performed in our institu-
tion, in pregnant HIV positive (N=23). The sample was
obtained from the database which included all HIV-
infected pregnant woman who gave birth between 1996
and 2009 (n= 731), in our institution. Data were col-
lected in order to obtain: demographic characteristics of
the sample, HIV subtype and its transmission category,
antiretroviral therapy, gestational age, indication of
amniocentesis, viral load and T CD4+ lymphocyte count
determined close to performing amniocentesis and close
to labour, result of the chromosomal analysis, obstetrical
complications, type of labour and data referring to the
newborn. Our sample was divided in two subgroups:
one comprising women with adequate pregnancy sur-
veillance in our immunodepression unit (Group A,
n=17) and other comprising women with the diagnosis
of HIV infection after performing amniocentesis, with
no surveillance or therapy until the amniocentesis
(Group B, n=6).
Summary of results
Among the 23 newborns, only one case of HIV 1 infec-
tion was diagnosed, in group B. It occurred in a patient
with a diagnosis of HIV infection at 30 weeks gestation,
after being submitted to amniocentesis at 16 weeks
gestation for primary CMV maternal infection, and she
had a vaginal delivery at 38 weeks. Antiretroviral ther-
apy was not accomplished as well as adequate pregnancy
surveillance.
Conclusions
When there is an indication to perform an amniocent-
esis in a pregnant woman infected with HIV, it is legiti-
mate to perform it if the woman is following a HAART,
and is ideally under viral suppression. Although the
number of our sample is limited, there was no case of
vertical transmission among pregnant women with ade-
quate pregnancy surveillance, who were submitted to
amniocentesis under HAART. It would be extremely
important to analyse wider results, in a multicentric
study.
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